Signatera: Using Tumor DNA in Blood to Guide Treatment After Surgery ↗
Compare MRD-guided treatment selection with patient-specific antigen design, without equating efficacy or indications.
Commercialization · TOPIC v1
From testing a patient's cancer to making their treatment
At what quality, turnaround time and cost can patient-specific medicines be supplied repeatedly?
Read article → From testing a patient's cancer to making their treatment
2026-10-24 05:23:44.516 UTC · Last recorded update
CURRENT READING
The company-reported phase 3 trial found two-year recurrence-free survival of 82.2% versus 70.0% after melanoma surgery. The expanded Tempus collaboration covers specimen collection and transfer, with sequencing subject to regulatory approvals.
Recorded editorial state, not a maturity score
- Phase 3 results reportedRecorded
- Assess regulation and supplyUnverified
- Commercial scale and costsUnverified
New question opened · v1
Record phase 3 results and supply roles, and track patient-level manufacturing and delivery conditions.
Permanent link to this revision ↗01 / WHAT WE TRACK
At what quality, turnaround time and cost can patient-specific medicines be supplied repeatedly?
02 / EVIDENCE & TECHNOLOGY
Individualized mRNA cancer vaccine / neoantigen selection / sequencing
03 / EDITORIAL READING
Because diagnostic data enter drug design, not just selection, the sequence of target selection, manufacturing, supply and clinical evaluation becomes a condition for the business.
04 / WHAT REMAINS UNKNOWN
Overall survival remains immature. The trial does not isolate algorithmic superiority; commercial pricing, supply scale and profitability remain unresolved.
05 / NEXT CHECK
Regulatory decisions, specimen-to-delivery time, manufacturing success, per-patient costs and indication-specific outcomes.
A hypothesis to keep honest
HYPOTHESIS · NOT YET TESTEDRepeatable target selection, supply and clinical evaluation may determine the scalability and viability of individualized treatment.
What would change our view: Trial delivery experience is not enough to infer viability if turnaround, failures or costs prevent practical clinical use.
A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.
Linked people & organizations
Open an entity to find its cardsINSTITUTION / INFRASTRUCTUREMerck & Co. ↗
Mentioned in this issue
INSTITUTION / INFRASTRUCTUREIntismeran autogene ↗
Mentioned in this issue
INSTITUTION / INFRASTRUCTUREPembrolizumab ↗
Mentioned in this issue
Related questions, optional follows
Map ↗Latest card updates
Latest 5 · editorial record dates- v1 · 2026-10-24 05:23:44.516 UTCNew question opened
Record phase 3 results and supply roles, and track patient-level manufacturing and delivery conditions.
Reading at the time: The company-reported phase 3 trial found two-year recurrence-free survival of 82.2% versus 70.0% after melanoma surgery. The expanded Tempus collaboration covers specimen collection and transfer, with sequencing subject to regulatory approvals.
Earlier updates (0)
Earlier entries will appear here once more than five reader-facing revisions have accumulated.
Background readings
Source dates and verification scope
Intismeran autogene: end-to-end design and manufacturing pathway ↗
JCO Oncology Advances · 2026-08-24 · peer-reviewed-technical-report
Multi-year collaboration with Moderna and Merck ↗
Tempus · 2026-10-07 · company-announcement
INTerpath-001 phase 3 results: intismeran autogene plus pembrolizumab ↗
Merck / Moderna · 2026-10-22 · company-announcement
This issue’s insight
Shared knowledge and the data each patient still needs →
Reusable shared knowledge differs from information that must be measured for each patient. Where does business value arise as more data become public?